Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference

Jan 4, 2021 | Press Releases

MARLBOROUGH, Mass., Jan. 4, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

Nov 19, 2020 | Press Releases

MARLBOROUGH, Mass., Nov. 19, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 10, 2020 | Press Releases

MARLBOROUGH, Mass., Nov. 10, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment

Nov 9, 2020 | Press Releases

The new data was presented at the SITC 2020 Virtual Scientific ProgramMARLBOROUGH, Mass., Nov. 9, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary...

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 26, 2020 | Press Releases

MARLBOROUGH, Mass., Oct. 26, 2020 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...